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ess: s.kharitonov@impeSummary Several nasal nitric oxide (NO) measurement techniques have been
described, but there is not a widespread measurement technique for measurement
of nasal NO. In this study we evaluated the repeatability of one technique of nasal
NO measurements using the nasal application of the NIOXs system.
Methods: Three nasal NO measurements (NIOXs Nitric Oxide Monitoring System,
Aerocrine, Sweden) were made on a single occasion in 22 healthy subjects and 27
patients with asthma, aged 5–69 years. Nasal NO was sampled during breath hold
from one nostril at a flow rate of 5ml/s.
Results: The repeatability of nasal NO assessed by the coefficient of variation (CV)
was 12.5% (95% Confidence interval (CI) 11.0–14.7%) for the total population.
Healthy adults had a significantly better repeatability than healthy children
(Po0:008). The mean NO level for the total population was 837 ppb. The mean NO
levels in children were lower than in the adults (751 and 897 ppb, respectively). The
mean breath hold length needed to obtain a steady NO plateau for all subject
categories combined was 20.476.01 s. The average number of attempts needed to
obtain three approved NO measurements was 5.4 (range 3–13) for the total
population. There were no significant differences between the different subject
categories. When using two measurements per session instead of three, the overall
CV was 10.5% (95% CI 8.8–13.1%). Most subjects found the measurements easy to
perform and all of them would accept to do the examination as a routine.
Conclusions: Nasal NO measurements in NIOX may provide a useful reliable clinical
tool to assess and monitor upper airways in different diseases, for example PCD and
rhinitis, and are acceptable by both healthy and asthmatic adults and children, as a
part of their routine visit to a physician.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Single expiratory flow exhaled nitric oxide mea-
surements are simple, highly reproducible,1 and
have been successfully used to diagnose,2 and to
monitor, predominantly larger airway inflammation
in asthma.3
The levels of NO derived from the upper respira-
tory tract are over 100-fold higher than exhaled NO
derived from lower airways. This fact is mostly due
to its high production in human paranasal sinuses4
which is due to high basal activity of constitutively
expressed form of nitric oxide synthase 2 (NOS2).5
Although nasal NO was not significantly different
from controls in the non-pollen season,6 it has been
shown that nasal NO can serve as a potential marker
of upper airway inflammation in allergic rhinitis and
perennial rhinitis,7,8 which is reduced by treatment
with nasal corticosteroids.8,9 In addition, exhaled
NO is also significantly elevated in allergic rhinitis in
the non-pollen season and is increased further in the
pollen season.6 However, the differences between
the levels of nasal NO in rhinitis compared with
normal subjects are much less marked than the
differences between exhaled NO between patients
with asthma and normal subjects because of the
very high baseline values. This makes nasal NO less
useful for diagnosis and monitoring treatment in
rhinitis than exhaled NO in asthma. However, in
house dust mite allergic subjects with persistent
rhinitis, the occurrence of high nasal symptom
scores were significantly associated with bronchial
symptoms and a higher exhaled NO.10 This possibly
places these subjects at more of a risk of developing
asthmatic symptoms, and may underline potential
importance of regular nasal NO assessment, as well
as exhaled NO.
The diagnosis of primary ciliary dyskinesia (PCD),
a clinical syndrome that overlaps with other
disorders, may be missed, or delayed, if the disease
is not associated with all the classic features,
particularly situs inversus. It has been decisively
shown that nasal NO is dramatically reduced in PCD
11 and measurement of nasal NO can be used in
clinical practice in various specialities to screen
suspected patients for PCD, both adults 12,13 and
children.14,15 Such extreme low values of exhaled
and nasal NO are not seen in any other condition
and are therefore of diagnostic value. There is no
easy, reliable screening test for PCD, and thus, the
majority of patients remain undiagnosed. There-
fore, measurement of nasal NO might be used as a
screening procedure to detect PCD amongst pa-
tients with recurrent chest infections or male
infertility due to immotile spermatozoa, and the
diagnosis of PCD is then confirmed by the sacchar-ine test, nasal nitric oxide, ciliary beat frequency
and electron microscopy.16 As with exhaled NO
measurements, nasal NO levels are abnormally low
in cystic fibrosis,17,18 although not to the same
extent as seen in PCD. Nevertheless, nasal NO
measurements may prove helpful in the differential
diagnosis of this condition.
Several nasal NO measurement techniques have
been described: tidal nasal breathing; fixed flow
exhalation; nasal–oral aspiration; aspiration from
one nares; nasal insufflation (NO sampled from one
nares as air is insufflated into the other nares at a
certain flow with velum closure).19 Recent Guide-
lines are available for nasal NO measurement 20 but
there is no standardised measurement technique
consistently used for measurement of nasal NO. In
this study we evaluated the repeatability of nasal
NO measurements when using the nasal application
of the NIOXs system.Methods
Aim of the study, subjects
This was an open, exploratory, observational pilot-
study in 22 healthy subjects and 27 patients with
asthma (in total 57 subjects were screened and 49
were enrolled) to determine the repeatability of
nasal NO measurements using the NIOXs Nitric Oxide
Monitoring system. Two subjects were not included
in the study due to technical problems and not being
able to perform the nasal NO measurements. Neither
nasal steroids nor decongestants were used by the
studied patients. None of the patients were smokers.
All subjects included completed the study. Six of the
included subjects were excluded from the statistical
analyses due to major protocol violations: nasal NO
measurements not performed according to protocol
in two subjects; nasal NO values are not available for
four subjects. The study was approved by the Ethics
Committee of the Royal Brompton Hospital and
Harefield NHS Trust.
Study design
Demographic data including date of birth, gender,
race, height and weight and information about any
strenuous physical activity performed within 1 h
before the nasal NO measurements (Table 1),
current medication and medical history were
recorded (Table 2). None of the studied subjects
had recent (4 weeks prior the study) upper
respiratory tract infection, chest infection or COPD
exacerbation, and all of them were advised not to
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Table 1 Demographic characteristics.
Variable Parameters Subject category
Asthma Healthy
Children Adults Children Adults
Age (years) Total reporting 12 15 8 14
Mean7SD 9.373.62 42.9713.74 12.273.03 32.775.71
Minimum 4.5 20.0 6.1 22.8
Maximum 17.1 69.0 15.6 45.6
Gender Female 5 6 4 9
Male 7 9 4 5
Table 2 Distribution of subjects and type of medication taken regularly or on the day of the visit, prior to the
nNO measurements.
Medication Subject category
Asthmatics Healthy
Children Adults Children Adults
Inhaled corticosteroid 7 12 0 0
Systemic corticosteroid 0 2 0 0
Short-acting bronchodilator 14 13 0 0
Long-acting bronchodilator 5 4 0 0
Leukotriene receptor agonist 0 2 0 0
Antihistamine 0 1 0 0
Other 0 1 0 1
None 0 0 8 13
Nasal nitric oxide in healthy and asthmatic adults and children 1107consume any nitrate-enriched food (i.e. spinach)
during and before the study visits. Consenting
subjects were guided through a short practice
session with the NIOXs equipment. Each subject
performed three nasal NO measurements according
to the instructions. If, in the judgment of the
investigator, a measurement was not performed
according to the instructions the measurement was
repeated. Each subject did not perform more than
totally 10 attempts. After each measurement
session (three approved measurements), all sub-
jects were asked four questions to ascertain the
adequacy of the information about the measure-
ment procedure, and to elicit any subjective
experience of discomfort or adverse event(s).
Altogether, the measurements, analyses and ques-
tionnaire were performed within no longer than
30min. There was no run-in period or follow-up in
the study.
Nasal NO measurements
The procedure for online measurement of nasal NO
generally followed the
’ ’
Recommendations forstandardised procedures for the online and offline
measurement of exhaled lower respiratory nitric
oxide and nasal nitric oxide in adults and children’’
which has been compiled by the American Thoracic
Society.20 NIOX analyser was calibrated every 13
days with the certified calibration gases (200 ppb
for exhaled NO and 2000 ppb for nasal NO; Linde
gas, Hoek Loos Speciality Gases, Amsterdam). The
subject should not have been engaged in any
strenuous physical activity during the last 60min
prior to testing. The Nasal mode view of the NIOXs
system (Aerocrine AB, Sweden) was used for nasal
NO measurements. An automatic measurement
stop was set to 40 s. The calculation range was
initially set to 15–18 s. The subject was seated
comfortably with the instrument at a convenient
position in front of him/her. The ambient NO value
displayed on the NIOXs screen was read and
recorded in the subject’s CRF. The ambient NO
value was subtracted from the NO values by the
statistician when the data were analysed. The
subject was asked to insert a NIOXs nasal olive in
one of the nostrils (the same nostril was used for all
measurements within the same subject) and
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(the time was chosen in order to facilitate the
procedure in the 5–6 year old age group). There-
after, the subject should inhale to TLC over 2–3 s
with the mouth open, close the mouth and hold the
breath as long as possible. No oral exhalation
against a resistance was performed. The measure-
ment was started by the operator when the subject
closed their mouth. The olive should be held tightly
against the nostril during the measurement to
prevent leakage of air. The aspirated air was
continuously sampled by the NO instrument during
the sampling period and the resultant NO graph
was displayed on the screen. The measurements
were performed at an aspiration flow rate of
5ml/s. The aspiration flow was measured online
and controlled by the NIOXs instrument. This is
important as the NO output is highly flow depen-
dent. The measurement was stopped by the
operator when the breath hold was stopped (when
shorter than 40 s). By looking at the NO graph
displayed, the investigator selected the time
period during which the average NO was calcu-
lated. The average NO value was calculated during
the first 3 s of the interval by the Investigator
considered as a steady NO plateau. For subjects
who did not reach a steady plateau, the NO average
was calculated during the first three of the four last
seconds of the breath hold.
A measurement, in the judgment of the investi-
gator was performed according to the instruc-
tions was an approved measurement. The procedure
was repeated until three approved measurements
were obtained. The three measurements should be
completed within 30min and the interval between
two measurements should be at least 30 s. Each
subject did not perform more than totally 10
attempts.
In the last 13 subjects a revised measurement
procedure was used to facilitate the performance
of children 5–6 years old. In the revised procedures
the subjects performed 5 s of tidal breathing before
measurement was started, whereas there was no
tidal breathing in the original procedure.Subjective experience of nasal NO
measurements
The following questions were asked of all subjects
after the measurement session (three approved
measurements) was completed:(a) Did you find the information about the mea-
surements to be adequate and easy to under-
stand? If No, please specify;(b) Did you find it easy to perform the manoeuvre
as directed by the investigator and the written
information? If No, please specify;(c) Have you experienced any discomfort, stress or
any unusual or unpleasant events during this
test?(d) If asked, would you accept to do this examina-
tion (three measurements) as part of a routine
visit to your doctor if it could be of help in
monitoring asthma and selecting appropriate
drug treatment and dosing? If No, please
specify.Safety assessments
In addition, before each nasal measurement session
was started, all subjects were asked to report any
abnormal sensation or untoward events, which may
occur in association with the procedure. Lastly,
after completion of the measurements, all subjects
were asked:
’ ’
Have you experienced any discomfort
or any unusual or unpleasant events during this
test?’’.Statistical methods
The primary objective in this study was to give
point and 95% confidence interval (CI) estimates of
the intra-individual precision (repeatability), which
is the square root of variance, s2; when measuring
nasal NO three times in a sequence. Repeatability
was described as the estimate of the coefficient of
variation, CV, i.e. the ratio between the within
standard deviation and the mean of the individual
nasal measurements. Confidence intervals for CV
were computed using the w2 distribution. The
repeatability was also visualised using the Blan-
d–Altman technique. A graph has been produced
where x-axis presents the session mean NO and
y-axis the differences between the mean NO and
the three individual measurements of NO. The
Bland–Altman limits of agreement have also been
displayed. The same statistical method, as de-
scribed above, has also been applied when analys-
ing the repeatability when using two measurements
instead of three. Point and interval estimates of the
repeatability, breath hold length, acceptability
(per cent of the subjects giving positive answers
to the four questions in the questionnaire), and
success rate were calculated for the whole sample
and for groups within the sample. Depending on
estimates of the distributions of these variables,
parametric or non-parametric statistics were used.
ARTICLE IN PRESS
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Repeatability of nasal NO measurements
Primary endpoint
The primary endpoint was the intra-individual
standard deviation or relative standard deviation,
CV. The results are shown in Table 3. The CV was
12.5% (95% CI 11.0–14.7%) for the total population.
Healthy adults had a significantly better repeat-
ability than healthy children (Po0:008). The mean
NO level for the total population was 8377320 ppb.
The mean NO level in children was lower than in
the adults (751 and 897 ppb, respectively).
Secondary endpoints
The secondary endpoints were the following: (1) To
assess the average breath-hold length needed to
obtain a steady NO plateau in different age groups;
(2) To assess the success rate in different age
groups. Success rate was defined as the number of
attempts needed to obtain three approved nasal
NO measurements; (3) To assess the repeatability
of measurement using two measurements per
session instead of three measurements per session;
(4) To assess the acceptability of the method in
different age groups using a subjective experience
questionnaire.
Average breath-hold
The mean breathhold length needed to obtain a
steady nasal NO plateau for all subject categories
combined was 20.476.01 s (Fig. 1). The breathhold
length for children (healthy 15.872.23 s; asthmaTable 3 Repeatability of nasal NO measurements adjuste
Subjects n Mean nNO (ppb)
Healthy
Children 8 843
Adults 14 879
Total 22 866
Asthma
Children 12 691
Adults 15 913
Total 27 814
Combined
Children 20 751
Adults 29 897
Total 49 837
s, estimate of the mean pooled within SD, CV estimate of the mean
limits for CV.19.976.39 s) was significantly shorter than for
adults (healthy 22.676.80 s; asthma 21.275.32 s;
Po0:001) in comparisons of breathhold lengths for
different subject categories. There was no signifi-
cant difference between asthmatic (20.675.73 s)
and healthy subjects (20.176.45 s) combined.
When comparing children and adults, in the healthy
group children had a significantly shorter breath
hold length than adults (Po0:001) but in the
asthmatic group the difference was not statistically
significant. In the last 13 subjects a revised
measurement procedure was used to facilitate the
performance of children 5–6 years old. In the
revised procedures the subjects performed 5 s of
tidal breathing before measurement was started,
whereas there was no tidal breathing in the original
procedure. When comparing the mean breath hold
length needed to obtain a steady NO plateau for
the two different measurement procedures, it
appeared that this time increased from
18.975.21 to 24.476.44 s when using the revised
measurement procedure.
Success rate in different age groups
The average number of attempts needed to obtain
three approved nasal NO measurements was 5.4
(range 3–13) for the total population (Fig. 2). There
were no significant differences between the differ-
ent subject categories. The number of plateaus
reached by the adult subjects was significantly
higher than for the children (Po0:046). There was
no significant difference between healthy
and asthmatics (Fig. 3). When comparing the
younger children (5–7 years) with the older onesd for ambient NO for the different subject categories.
s CV 95% CI, CV
LL UL
152 18.0 13.4 27.4
68 7.7 6.2 10.5
106 12.3 10.2 15.5
103 14.9 11.8 21.4
103 11.2 9.1 15.4
103 12.6 10.8 15.9
125 16.6 13.8 21.6
88 9.8 8.3 12.1
104 12.5 11.0 14.7
pooled within CV, LL and UL lower and upper 95% confidence
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Figure 2 The mean breathhold length needed to obtain a
steady nasal NO plateau for all subject categories.
Figure 3 The average number of attempts needed to
obtain three approved NO measurements.Figure 1 Bland–Altman analysis for the repeatability of
nasal NO (difference was computed as the first–second
measurement. If first or second measurement was missing
the third measurement was used. Means computed in the
same way. The mean difference was 6.53 ppb and the SD
of the difference was 125.5 ppb. This yields the
’ ’
limits of
agreement’’ 6.532 125.5 ¼ 257 ppb and 6:53þ
2 125:5 ¼ 245ppb).
S.A. Kharitonov et al.1110(47 years), the mean number of plateaus reached
was 2.371.11 and 2.670.82, respectively (not
statistically significant).Repeatability of measurements using two
measurements instead of three
The overall coefficient of variation was 10.5% (95%
CI 8.8–13.1%) when using two approved nasal NOmeasurement instead of three. Healthy adults had
a significantly better repeatability than healthy
children (Po0:013) (Table 4).
Acceptability of the method in different age
groups
Most subjects found the measurements easy to
perform and all of them would accept to do the
examination as a routine (Table 5).Discussion
Summary of the results
Adults had a significantly better repeatability than
children who also had lower nasal NO levels. The
mean breath hold length needed to obtain a steady
nasal NO plateau was not different in any group.
Neither were there any significant differences
between the different subject categories in the
number of attempts needed to obtain three
approved nasal NO measurements. When using
two measurements per session instead of three,
the overall coefficient of variation was similar if not
slightly better. Healthy adults, however, had a
significantly better repeatability than healthy
children. Most subjects found the measurements
easy to perform and all of them would accept to do
the examination as a routine.
Repeatability of measurements
Identifying the intrinsic error of this novel techni-
que is of critical importance for the potential
ARTICLE IN PRESS
Table 4 Repeatability of nasal NO measurements adjusted for ambient NO using two measurements per session
instead of three.
Subjects n Mean nNO (ppb) s CV 95% CI, CV
LL UL
Healthy
Children 8 864.6 31.5 3.6 2.5 7.0
Adults 14 866.9 54.1 6.2 4.6 9.8
Total 22 866.1 47.2 5.4 4.2 7.7
Asthma
Children 12 692.3 123.0 17.8 12.7 29.3
Adults 15 905.0 99.5 11.0 8.1 17.0
Total 27 806.8 110.6 13.7 10.8 18.6
Combined
Children 20 761.2 97.4 12.8 9.8 18.5
Adults 29 885.9 80.9 9.1 7.3 12.3
Total 49 834.0 88.0 10.5 8.8 13.1
s, estimate of the mean pooled within SD, CV estimate of the mean pooled within CV, LL and UL lower and upper 95% confidence
limits for CV.
The first two measurements have been used for the calculations (in cases where the first or the second measurement was
missing, the third exhalation has been used instead).
Table 5 Acceptability of method.
Question Answer Comments
Yes No
Information adequate and easy
to understand?
55 (100) 0 (0)
Performance easy? 48 (87.3) 7 (12.7) Six subjects found it difficult to hold
their breath. For one subject, the
comment is missing
Discomfort or stress? 1 (1.8) 54 (98.2) Comment is missing for one subject
Accept as routine? 55 (100) 0 (0)
n, number of answers; %, percent of the answers.
Nasal nitric oxide in healthy and asthmatic adults and children 1111clinical utility of the nasal NO parameters in
differential diagnosis and monitoring of upper
respiratory tract inflammation.
NIOX nasal application can be used to determine
the concentration of NO in gas sampled from one
nostril at a flow rate of 5ml/s.20 Nasal NO
measured using an aspiration technique,21 aspirat-
ing room air through the nasal cavities by means of
a Teflon nozzle placed in one nasal vestibule while
maintaining velopharyngeal closure using a party
’ ’
blow-out’’ toy has shown a considerable varia-
bility in the values for nasal NO output in normal
children.22Usually, nasal NO is measured in both adults and
children sitting with an olive inserted inside one
nostril ensuring a tight seal while the contralateral
nostril is left open. Air was continuously sampled at
a constant transnasal flow rate ranging from 5 8 to
20ml/s 15 with the soft palate closed. The constant
transnasal flow produced a washout phase of NO
followed by the establishment of a steady plateau
documented in the profile of NO. However, even
the most recent papers have not reported on
variability of nasal NO measurements.15
Reproducibility of exhaled NO (FENO) measure-
ments within a single day in both adults (intraclass
ARTICLE IN PRESS
Figure 4 The number of plateaus reached by the
subjects to reached per measurement session.
S.A. Kharitonov et al.1112correlation, ICC 0.94) and children (ICC 0.94) is
superior to any conventional methods of airway
inflammation monitoring in asthma.1
It has been reported that intra-subject coeffi-
cient of variation of quiet nasal exhalation ranged
between 5%, 13% and 12% in subjects with allergic
nasal polyposis, allergic rhinitis and healthy sub-
jects, respectively,23 which was similar to 14% in
adults with allergic rhinitis.24
Coefficient of variation of nasal NO between 8%
and 10% was reported for healthy children and
adults,14 but other authors reported much lower
variability of nasal NO measurements (the coeffi-
cient of variation of three consecutive NO measure-
ments o3%) for either on- or off-line nasal NO.25
Interestingly, by introducing repeated humming
manoeuvres before measurements, the intra-indi-
vidual variation was reduced.23 This, as the authors
speculate, may be due to a great increase in nasal
NO levels during humming or speaking, as humming
is an extremely effective means of increasing sinus
ventilation where almost the entire volume of a
normal maxillary sinus is exchanged during phona-
tion as compared with less than 5% during quiet
exhalation. Moreover, either resonance or volume
of communicating nasal cavities can modulate nasal
NO output too.23 This may further explain the
larger variation of nasal NO levels that we have
observed in the same subject when freely speaking
or being silent for 3min before the test, a period of
time which may allow for a variable contribution of
NO from paranasal sinuses to the nose.23 It has been
suggested that the modality of quiet nasal exhala-
tion (e.g. the period of silence before the test)
during nasal NO measurement should be consid-
ered. It may also be that nasal NO measured after
repeated humming may represent a more reliable
measure of the nasal mucosal NO output with less
contribution from the paranasal sinuses.
Sweat conductivity, a standard current practice
to diagnose cystic fibrosis (CF) by measuring sweat
NaCl concentration, lacks reproducibility owing to
physiological variations (patient’s diet, tempera-
ture, and other factors at present unrecognized).26
For example, sweat conductivity determined once
a week for 5 consecutive weeks on healthy
volunteers, including healthy infants and known
CF patients have demonstrated a within- and
between-subject biological variations of 12.0%
and 30.0%, respectively, for healthy controls; 18%
and 20% for healthy infants; and 7.3% and 6.5% for
CF patients, respectively.27
The mean pooled SD of all nasal NO measurements
in our study was 104 (95% CI 92–123 ppb, based on
the w2 distribution). These results suggest that if a
patient’s nasal NO levels change more than 2SD(208 ppb) (Fig. 4) between sessions, or will be
different from healthy controls it is more likely due
to either the inflammatory process or PCD rather
than inaccuracy of the NIOX device. This finding is
valuable for potential use of nasal NO measure-
ments in routine clinical practice. Diagnostic
properties of nasal NO and it’s role in short-term
monitoring, when the measurements of upper
airway inflammation are made more often is
particularly important.Success rate in different age groups
The success rate as judged by the number of
attempts needed to obtain three approved nasal
NO measurements was not different in the age
groups, except for the number of plateaus reached,
which was significantly higher in adults. Other
authors, although using a different NO analyser,
reported rather high proportion of failures (16% and
5% failures in adults and children, respectively) to
obtain an acceptable nasal NO measurement.14Acceptability of the method
The simplicity of the standardised nasal NO method
used in our study was further enhanced by the
design of the NIOXs system, which controls the NO
plateau values and ensures that the measurements
will not be accepted unless they are performed
according to the predefined parameters. The
youngest child in our study was a 4.5-year-old child
who was able to perform the test. Therefore, use of
nasal NO as a relatively simple screening tool seems
justified and can be performed from about the age
of 5 years with minimal coaching, and the results
are very repeatable.
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adequate nasal NO values
Sampling and acquisition time that is needed to
obtain repeatable nasal NO values without making
the test impractical, especially in children, is in the
range between 20 and 30 s.8,13,15 Recently reported
nasal NO measurements that were obtained during
a plateau lasting for at least 10 s, approximately
after 20–30 s of acquisition time (total 40 s) may be
adequate in adults,28 but not in young children.
The mean breathhold length needed to obtain a
steady nasal NO plateau for all subject categories
was, approximately 20 s, without any significant
difference between asthmatic and healthy sub-
jects, and was completed by all the children.Number of nasal NO measurements per
session
The number of nasal NO measurements per
measurement session is usually three,8,13,15
although some authors reported six tests per
session,28 which is obviously excessive and may
prevent the use of nasal NO in clinical practice. Our
current study demonstrates that when using two
measurements per session instead of three, the
overall coefficient of variation was similar if not
slightly better. This may be of great advantage, as
it will shorten the time needed for the measure-
ment procedure.Conclusion
Our data suggest that standardized nasal NO
measurements may provide a useful reliable clin-
ical tool to assess and monitor upper airways in
different diseases, for example PCD and rhinitis,
and are acceptable by both healthy and asthmatic,
adults and children, as a part of their routine visit
to a physician.References
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